TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33135120

Group type: EXPERIMENTAL
Intervention: Smartphone-based self-reported activity
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Automatically-generated smartphone-based activity measurements
Number of subjects: 366

Group type: COMPARATOR
Intervention: Daily self-reported activity in patients with BD
Number of subjects: 366

Group type: COMPARATOR
Intervention: Physical activity (number of steps) in patients with BD
Number of subjects: 366

Group type: COMPARATOR
Intervention: Social activity (missed calls) in patients with BD
Number of subjects: 366

Group type: COMPARATOR
Intervention: Call duration in patients with BD
Number of subjects: 366

Group type: COMPARATOR
Intervention: Physical activity in unaffected relatives (UR)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Daily self-reported activity in unaffected relatives (UR)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Social activity in unaffected relatives (UR)
Number of subjects: 366
Study: 33135537

Group type: EXPERIMENTAL
Intervention: Contrast bath (CB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without CRPS)
Number of subjects: 20
Study: 33135728

Group type: EXPERIMENTAL
Intervention: 12,13-diHOME in human milk
Number of subjects: 58
Study: 33135811

Group type: EXPERIMENTAL
Intervention: Specialised early intervention (SEI) teams
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1145
Study: 33135812

Group type: EXPERIMENTAL
Intervention: Extended SEI
Number of subjects: 780
Study: 33136058

Group type: EXPERIMENTAL
Intervention: Injectable Amoxicillin every 12 hours plus once-daily injectable Gentamicin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Injectable Ampicillin every 6 hours plus once-daily injectable Gentamicin
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Injectable Amoxicillin plus Gentamicin
Number of subjects: 308
Study: 33136507

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0
Study: 33137019

Group type: EXPERIMENTAL
Intervention: PRESERFLO MicroShunt implantation with adjunctive mitomycin C (0.4 mg/mL)
Number of subjects: 23
Study: 33137021

Group type: EXPERIMENTAL
Intervention: 24-hour contact lens sensor (CLS, Triggerfish) recording of intraocular pressure (IOP)-related ocular dimensional changes
Number of subjects: 32
Study: 33137293

Group type: EXPERIMENTAL
Intervention: Setmelanotide (open-label for 12 weeks, followed by an 8-week placebo-controlled withdrawal sequence and 32 weeks of open-label treatment)
Number of subjects: 21
Study: 33137635

Group type: EXPERIMENTAL
Intervention: Gradual head positioning (GHP) changes from 5-min FLAT to SIT head position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIT head position after 5-min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study: 33138623

Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 0
Study: 33138835

Group type: EXPERIMENTAL
Intervention: Early BC on treatment post-surgery (Group 1, 89 patients)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Early BC after completion of adjuvant treatment (Group 2, 108 patients)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Metastatic BC treatment (Group 3, 102 patients)
Number of subjects: 299
Study: 33138839

Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS patients requiring mechanical ventilation (MV)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Plasma and ELF CXCL10 concentrations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ELF concentrations of mitochondrial DNA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inflammatory mediators in COVID-19 ARDS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CXCL10 as a candidate biomarker
Number of subjects: 28
Study: 33138848

Group type: EXPERIMENTAL
Intervention: Mouthwash containing antivirals (β-cyclodextrin and Citrox®)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 206
Study: 33138866

Group type: EXPERIMENTAL
Intervention: Buparlisib at a starting dose of 100 mg daily
Number of subjects: 50
Study: 33138974

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation for a median time of 11 days (IQR 6-14)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Vasopressors
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Age (OR, 1.05; 95% CI, 1.02-1.08; p<0.001)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels upon ICU admission (1.008; 95% CI, 1.003-1.012; p<0.001)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 164
Study: 33139055

Group type: EXPERIMENTAL
Intervention: Volasertib + Itraconazole (Cycle 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volasertib monotherapy (Cycle 2)
Number of subjects: 0
Study: 33139139

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine with Matrix-M™ adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 0
Study: 33139266

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 30
Study: 33139350

Group type: EXPERIMENTAL
Intervention: Laronidase enzyme replacement therapy (ERT)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 740
Study: 33139388

Group type: EXPERIMENTAL
Intervention: Clinical Chemistry Score (CCS) using Ortho Clinical Diagnostics high-sensitivity cardiac troponin I (hs-cTnI) assay in cohort 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical Chemistry Score (CCS) using Abbott Diagnostics hs-cTnI assay in cohort 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: hs-cTnI alone (published cut-offs)
Number of subjects: 0
Study: 33140173

Group type: EXPERIMENTAL
Intervention: CRT-targeted fluid resuscitation (CRT-T)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lactate-targeted fluid resuscitation (LAC-T)
Number of subjects: 42
Study: 33140460

Group type: EXPERIMENTAL
Intervention: 4 days of nicotinised cigarette smoking
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Acute cigarette smoking (nicotinised)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Exposure to smoking-related cues
Number of subjects: 27
Study: 33140664

Group type: EXPERIMENTAL
Intervention: Parsaclisib (INCB050465), a highly selective PI3Kδ inhibitor, used as monotherapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 33141094

Group type: EXPERIMENTAL
Intervention: Remote titration facilitated by a smartphone-based telemonitoring system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 42
Study: 33141101

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anaerobic exercise group (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual group (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chair-Stand test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Measurements of circulating cell-free DNA and extracellular vesicles
Number of subjects: 30
Study: 33141103

Group type: EXPERIMENTAL
Intervention: 13-week online intervention for increasing physical activity
Number of subjects: 79

Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 79
Study: 33141170

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 4668

Group type: COMPARATOR
Intervention: Not treated
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: Initiating treatment
Number of subjects: 4668
Study: 33141172

Group type: EXPERIMENTAL
Intervention: 18F-flortaucipir PET
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitively normal controls
Number of subjects: 20
Study: 33141188

Group type: EXPERIMENTAL
Intervention: RESILIA aortic bioprosthesis
Number of subjects: 133
Study: 33141449

Group type: COMPARATOR
Intervention: Phlebotonics (various types including rutosides, hidrosmine, diosmine, calcium dobesilate, etc.)
Number of subjects: 7690

Group type: COMPARATOR
Intervention: Phlebotonics
Number of subjects: 7690
Study: 33142006

Group type: EXPERIMENTAL
Intervention: Smartphone app with personalized plasma renin activity (PRA) recommendations; clinicians followed app's recommendations (n=16, 55%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Smartphone app with personalized plasma renin activity (PRA) recommendations; clinicians did not follow app's recommendations (n=13, 45%)
Number of subjects: 29
Study: 33142018

Group type: EXPERIMENTAL
Intervention: Concomitant administration of efflux transporter inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapeutics that cause CIPN (taxanes, platins, vincristine, bortezomib, epothilones, thalidomide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic variants in efflux transporters
Number of subjects: 0
Study: 33142029

Group type: EXPERIMENTAL
Intervention: p16/Ki-67 assay
Number of subjects: 3100
Study: 33142068

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transfer (FMT) - three repeated FMTs (day 0, two weeks, four weeks)
Number of subjects: 9
Study: 33142850

Group type: EXPERIMENTAL
Intervention: Motor program activating therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vojta's reflex locomotion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 33143665

Group type: EXPERIMENTAL
Intervention: Fitbit® activity monitor and 'Bupa Boost' smartphone app
Number of subjects: 180
Study: 33144080

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33144166

Group type: EXPERIMENTAL
Intervention: Discharged home
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Discharged to rehabilitation clinic or another institution
Number of subjects: 1902
Study: 33144239

Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE) antegrade approach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE) bidirectional approach
Number of subjects: 30
Study: 33144352

Group type: EXPERIMENTAL
Intervention: Higher plasma MGO levels
Number of subjects: 160
Study: 33145060

Group type: EXPERIMENTAL
Intervention: Eosinophilic COPD (blood eosinophil counts ≥300 cells/µL)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Non-eosinophilic COPD (blood eosinophil counts <300 cells/µL)
Number of subjects: 145
Study: 33145266

Group type: EXPERIMENTAL
Intervention: Apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death.
Number of subjects: 23
Study: 33145402

Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 1184

Group type: COMPARATOR
Intervention: HER2 amplification-positive patients
Number of subjects: 1184
Study: 33145494

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 33145616

Group type: EXPERIMENTAL
Intervention: Berzosertib (intravenous infusion)
Number of subjects: 240
Study: 33145694

Group type: EXPERIMENTAL
Intervention: Implementation strategies bundle (team activation, external facilitation, community of practice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of central champions in facilities
Number of subjects: 0
Study: 33145809

Group type: EXPERIMENTAL
Intervention: Low-Dose CT (LDCT) imaging for osteoporosis screening
Number of subjects: 69095
Study: 33146624

Group type: EXPERIMENTAL
Intervention: Standardized discharge prescription forms with 90-day prescriptions and 3 repeats for recommended cardiac medication classes, in combination with education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer (>60 days) versus shorter prescription durations
Number of subjects: 0
Study: 33146628

Group type: EXPERIMENTAL
Intervention: Novel DNA-based diagnostic assay for CNS infections
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Multiplex PCR-based meningitis/encephalitis (ME) panel
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Proteomics profiling of blood from children with severe CNS infection
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Myxovirus resistance protein A (MxA) as a biomarker in blood for viral CNS infection
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine against Streptococcus pneumoniae
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Carriage and invasive rate of Neisseria meningitidis
Number of subjects: 300
Study: 33146741

Group type: EXPERIMENTAL
Intervention: Cemiplimab 250 mg every 3 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 13
Study: 33146812

Group type: EXPERIMENTAL
Intervention: Type II papillae
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Type IIIb papillae
Number of subjects: 637

Group type: COMPARATOR
Intervention: Type I papillae
Number of subjects: 637
Study: 33146854

Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: presepsin
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: sTREM-1 and presepsin combined with CLIF-SOFA score
Number of subjects: 143

Group type: COMPARATOR
Intervention: Other biomarkers (WBC, PCT, CRP)
Number of subjects: 143
Study: 33146924

Group type: COMPARATOR
Intervention: Patients without DM
Number of subjects: 8968

Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 8968
Study: 33146953

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment on HT-7 for 5 weeks
Number of subjects: 30
Study: 33147086

Group type: EXPERIMENTAL
Intervention: Cumulative stigma experiences
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Stigma from family members and acts of overt discrimination
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Gender analysis
Number of subjects: 251
Study: 33147119

Group type: EXPERIMENTAL
Intervention: Sequential imaging with dual tracers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential use of PET tracers
Number of subjects: 0
Study: 33147165

Group type: EXPERIMENTAL
Intervention: Self-triage web application
Number of subjects: 735419
Study: 33147283

Group type: EXPERIMENTAL
Intervention: 3D regimen treatment
Number of subjects: 41
Study: 33147426

Group type: EXPERIMENTAL
Intervention: Implementation Intentions (II) training protocol
Number of subjects: 0
Study: 33147613

Group type: EXPERIMENTAL
Intervention: RA patients with MTX only or with other medications
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: RA patients with varying disease activity (DAS28 and CRP levels)
Number of subjects: 102
Study: 33148185

Group type: EXPERIMENTAL
Intervention: Patient Activation Measurement (PAM)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) measured with a 5-item Likert scale
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 605
Study: 33148190

Group type: EXPERIMENTAL
Intervention: Educational intervention for hospital staff (lectures, workshops, and small projects to increase person-centeredness).
Number of subjects: 99
Study: 33148216

Group type: EXPERIMENTAL
Intervention: Spanish BESTest
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spanish Mini-BESTest
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BESTest and Mini-BESTest total scores by sex
Number of subjects: 30
Study: 33148235

Group type: EXPERIMENTAL
Intervention: 3 µg epinephrine applied into the test well
Number of subjects: 21

Group type: COMPARATOR
Intervention: Physiological saline applied into the control well
Number of subjects: 21
Study: 33148261

Group type: EXPERIMENTAL
Intervention: e-Device (certolizumab pegol self-injection)
Number of subjects: 0
Study: 33148277

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin administration
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Intravenous insulin administration
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: IS and hyperglycemia without treatment
Number of subjects: 340

Group type: COMPARATOR
Intervention: Hyperglycemia without IS
Number of subjects: 340

Group type: COMPARATOR
Intervention: IS without hyperglycemia
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 340
Study: 33148330

Group type: EXPERIMENTAL
Intervention: RT-TMZ (concomitant temozolomide and radiotherapy)
Number of subjects: 52
Study: 33148673

Group type: EXPERIMENTAL
Intervention: BMS-986178 monotherapy (20-320 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: BMS-986178 plus nivolumab (240-480 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Nivolumab monotherapy (240-480 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: BMS-986178 plus ipilimumab (1-3 mg/kg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: BMS-986178 plus nivolumab plus ipilimumab
Number of subjects: 165
Study: 33148693

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four cycles then nivolumab 3 mg/kg every 2 weeks until progression or a maximum of 20 cycles.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab combination therapy
Number of subjects: 57
Study: 33148732

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1532
Study: 33148961

Group type: EXPERIMENTAL
Intervention: 6-week self-management program
Number of subjects: 62
Study: 33148977

Group type: EXPERIMENTAL
Intervention: COVID-19 infection in SOT recipients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplant activity during the pandemic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment strategies and vaccinations for COVID-19
Number of subjects: 0
Study: 33148993

Group type: EXPERIMENTAL
Intervention: MSMW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSMW-T
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSMO
Number of subjects: 0
Study: 33149005

Group type: EXPERIMENTAL
Intervention: Job demand
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Overinvestment
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Effort-reward imbalance (ERI)
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Job strain
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Isostrain
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Job demand-control-support model
Number of subjects: 3142

Group type: EXPERIMENTAL
Intervention: Effort-reward imbalance model
Number of subjects: 3142
Study: 33149182

Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 5113
Study: 33149400

Group type: EXPERIMENTAL
Intervention: 5% NaF (GI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% NaF with amorphous calcium phosphate (ACP) (GII)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% NaF with casein phosphopeptides - amorphous calcium phosphate (CPP-ACP) (GIII)
Number of subjects: 60
Study: 33149768

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy (ET)
Number of subjects: 306
Study: 33150137

Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions
Number of subjects: 92509

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 92509
Study: 33150319

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted group therapy (0.3-0.36 mg/kg po) with 8-10 group therapy visits and one psilocybin administration visit
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted group therapy
Number of subjects: 18
Study: 33150320

Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine (one or two doses)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine (two doses)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine
Number of subjects: 285
Study: 33150322

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12123
Study: 33150325

Group type: EXPERIMENTAL
Intervention: Chewable mebendazole tablet
Number of subjects: 397

Group type: COMPARATOR
Intervention: Solid mebendazole tablet
Number of subjects: 397
Study: 33150375

Group type: EXPERIMENTAL
Intervention: N95/PAPR mask
Number of subjects: 20614

Group type: COMPARATOR
Intervention: Surgical/other masks
Number of subjects: 20614

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 20614

Group type: EXPERIMENTAL
Intervention: Overall seropositivity
Number of subjects: 20614
Study: 33150388

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 348

Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 348
Study: 33150390

Group type: EXPERIMENTAL
Intervention: Lapatinib 1250 mg/day for 6 months
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 4
Study: 33150746

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study: 33150753

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: PVI + CTI
Number of subjects: 366
Study: 33150779

Group type: EXPERIMENTAL
Intervention: High-dose fish oil capsules
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33150834

Group type: EXPERIMENTAL
Intervention: Clofarabine, etoposide, and cyclophosphamide (CloEC)
Number of subjects: 7
Study: 33150947

Group type: EXPERIMENTAL
Intervention: High-load trials (8 letters)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Right dlPFC activity during high-load trials
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: dlPFC activity during threat
Number of subjects: 32

Group type: COMPARATOR
Intervention: Overall WM performance
Number of subjects: 32
Study: 33151515

Group type: EXPERIMENTAL
Intervention: Subjective caregiver assessments of consciousness
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subjective caregiver assessments of pain
Number of subjects: 12

Group type: COMPARATOR
Intervention: Objective neurophysiological measures of consciousness and pain
Number of subjects: 12
Study: 33151636

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 530